Board of Directors

Ms. Shaw is a first-generation entrepreneur with over 45 years of experience in the field of biotechnology. She is a recipient of ‘Padma Shri’ and the ‘Padma Bhushan’ awards. She was also conferred with the highest French distinction – Chevalier de l’Ordre national de la Legion d’honneur (Knight of the Legion of Honour) in 2016. She is a recipient of ICMR’s Lifetime Achievement Award for Outstanding Achievement in Healthcare in 2019. She was Honoured with Order of Australia, Australia’s highest civilian award and was named EY World Entrepreneur of the year in 2020. She is also the Chairperson of Biocon Limited, Independent Director on the Board of Trent Ltd and Narayana Hrudayalaya.

Siddharth Mittal is an accomplished business leader with close to three decades of experience spanning business leadership, strategy, business transformation, strategic finance, mergers & acquisitions, and enterprise value creation, Siddharth is responsible for the Company’s strategic direction, business performance and operational excellence to drive  long-term growth.

Prior to joining Syngene, Siddharth was with Biocon Limited since May 2013, where he joined as Chief Financial Officer before being appointed Managing Director and Chief Executive Officer in 2019. As CFO he played a pivotal role in strengthening the Company’s strategic finance agenda, leading strategic biosimilar partnerships with global partners, and driving shareholder value. He subsequently led the strategic spin-off of Biocon Biologics into an independent global biosimilars company enabling greater  focus across the biosimilars and generics businesses. He also played a key role in the Group’s corporate restructuring, including the US$ 1 billion Qualified Institutional Placement (QIP) and the consolidation of the biosimilars and generics businesses.

As Managing Director and CEO, Siddharth led Biocon’s diversified biopharmaceutical business, with responsibility spanning both the Generics and Novel Biologics portfolios. During this period, he transformed the Generics business by expanding its global manufacturing platform, strengthening commercial partnerships, and advancing its complex formulations portfolio – including the commercialization of the Company’s GLP-1 portfolio in key markets. He also   oversaw Biocon’s innovation-led Novel Biologics business, guiding the progression of its pipeline and partnerships, while reinforcing the Company’s position as an innovation-led global biopharmaceutical enterprise.

He currently serves as Co-President of IPSO (Innovative Pharmaceutical Services Organisation) and is a National Executive Committee member of FICCI.

Earlier in his career Siddharth worked with the audit practice of S.R. Batliboi & Co (an EY member firm) and thereafter held progressively senior finance positions at Cambridge Solutions and Symphony Teleca in the United States.

Siddharth holds a Bachelor of Commerce degree from Symbiosis College of Arts and Commerce, Pune. He is a Chartered Accountant from the Institute of Chartered Accountants of India and a Certified Public Accountant (CPA) from Colorado, USA. He is recognized for his strategic mindset, commercial acumen and execution-focused leadership style, along with a strong record of building high-performing teams, driving business transformation and creating sustainable value for customers, partners and shareholders.

Professor Rosenberg is the Canada Research Chair in the Future Internet, the Cisco Research Chair in 5G Systems and a professor in electrical and computer engineering at the University of Waterloo, Canada. She is a Fellow of the Institute of Electrical and Electronics Engineers and of the Canadian Academy of Engineering. At Syngene, she is Chairperson of the Corporate Social Responsibility Committee, and a member of the Nomination & Remuneration Committee, the Stakeholders Relationship & ESG Committee and the Science & Technology Committee.

Ms Bali is a global business leader with extensive experience in leading and transforming large companies both in India and overseas. She served as Chief Executive Officer & MD of Britannia Industries Ltd., from 2005 to 2014. Prior to that, she worked for The Coca-Cola Company and Cadbury Schweppes Plc in a variety of Marketing, General Management and Chief Executive roles in the UK, Nigeria, South Africa, USA and Chile. At present, she is a Non-Executive Director on the global boards of SATS Ltd and Cognizant Technology Solutions, and in India, she serves on the board of Bajaj Auto Limited. At Syngene, she is a member of the Nomination & Remuneration Committee, Audit Committee and the Corporate Social Responsibility Committee.

Ms Sharmila Abhay Karve is a Fellow of the Institute of Chartered Accountants of India. She retired as audit partner from Price Waterhouse in June 2019. During her tenure in Price Waterhouse, she was an engagement partner with several large Indian and multinational clients. She was appointed as the Chief Ethics Officer. In 2009, she was appointed as the Assurance Leader of the firm and was elevated to the role of Assurance Risk & Quality Leader in April 2012. In her last role as Global Diversity Leader since December 2016, Ms. Karve focussed her efforts on bringing more diversity throughout the PwC network. At present, she is a Director on the boards of CSB Bank Limited, EPL Limited, Vanaz Engineers Limited, Aadhar Housing Finance Limited and Thomas Cook (India) Limited in India. Her overseas directorships include Fairfax India Holdings Corporation, EPL Packaging (Guangzhou) Ltd., EPL America LLC, and Lamitube Technology Ltd, Mauritius. At Syngene, she is the Chairperson of the Audit Committee and a member of the Nomination and Remuneration Committee and the Corporate Social Responsibility Committee.

Dr Parmar holds an MD from Harvard Medical School, a Ph.D. in experimental pathology from Harvard University and a BA in molecular biology and medieval studies from Princeton University. Currently, he is a Managing Partner at 5AM Ventures, a life sciences venture capital firm headquartered in San Francisco. Dr Parmar serves on the Advisory Boards of Harvard Medical School, Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation. At Princeton University, Dr Parmar worked on developmental genetics with Nobel Laureate Eric F. Wieschaus. Dr Parmar also serves on the Boards of Ensoma, Entrada Therapeutics, GlycoEra, Precede, Rallybio, and is a founding member of the COVID R&D alliance. At Syngene, Dr Parmar is a member of the Risk Management Committee and the Science & Technology Committee.

Nilanjan Roy has deep experience in international finance as a result of his 33-year career in roles including Chief Financial Officer at Infosys Limited, Global Chief Financial Officer at Bharti Airtel Limited, and senior positions at Unilever. He has worked in a range of geographies in Europe, the United States and India.

Nilanjan’s broad expertise includes traditional finance functions such as treasury, mergers and acquisitions, investor relations, taxation, financial accounting, and reporting. Beyond this, his experience covers corporate governance, ESG (Environment, Social and Governance) and risk management. He has industry sector experience in information technology, telecommunications and consumer products.

Nilanjan holds a Bachelor of Commerce (Hons.) degree from Delhi University and is a Chartered Accountant. At Syngene, Nilanjan is the Chairperson of the Risk Management Committee and the Stakeholders Relationship & ESG Committee and is a member of the Audit Committee.

Manja Boerman is a distinguished leader in the biopharmaceutical industry with a deep specialization in protein, cell and gene therapy. With over 20 years of experience, she has played pivotal roles in numerous companies, significantly impacting the development and commercialization of advanced therapies. Manja’s career highlights include her tenure as President of Catalent Protein, Cell and Gene Therapy, Aesica Pharmaceuticals, Patheon Biologics, and DSM Biologics, as well as her leadership as CEO of Kiadis Pharma and Regenesance. She is currently the CEO of Prothya Biosolutions (a blood plasma product company).

Manja holds a PhD in Biochemistry from the State University of New York, reflecting her strong academic background in life sciences. She began her career at DSM, where she held various positions in business development, licensing, and technology within DSM Biologics. Throughout her career, Manja has been recognized for her expertise in clinical operations, strategic planning, and business development. She has contributed to numerous scientific publications and has been a prominent speaker at industry conferences. Her ability to drive growth and foster innovation has earned her a respected reputation in the biotechnology sector, particularly in start-up environments and global late-stage clinical development for cell therapy products.

At Syngene, she is the Chairperson of the Science and Technology Committee and a member of the Risk Management Committee, the Stakeholders Relationship & ESG Committee and the Nomination & Remuneration Committee.

Dr. Sanjaya Singh, who holds a Ph.D. in Molecular Biology from Banaras Hindu University and completed his postdoctoral research at the University of Texas MD Anderson Cancer Center, is a distinguished scientific leader with over 25 years of experience in the field of biotherapeutics. He is the Founder and Chief Scientific Officer of Third Arc Bio and has a proven track record of innovation across multiple therapeutic areas, including immunology, oncology, retinal, metabolic, and neurological diseases. He is a co-inventor of several breakthrough biologics, including SKYRIZI®, EBGLYSS™, PRAXBIND®, ligelizumab, and lampalizumab, many of which have received FDA breakthrough designations.

Dr. Singh previously served as Head of Janssen Biotherapeutics, where he led the global biotherapeutics discovery organization at Johnson & Johnson and defined the strategic direction for its expanding portfolio. Before that, he was Vice President of Biotherapeutics Discovery at Boehringer Ingelheim, where he successfully built and led a globally competitive preclinical and clinical pipeline. He began his industry career at Tanox Inc., heading the Biotherapeutics division until the company’s acquisition by Genentech.

In addition to his executive leadership roles, Dr. Singh co-founded Aliada Therapeutics, a neuroscience and blood-brain barrier platform company recently acquired by AbbVie, and currently serves as a Venture Partner at Omega Funds, a leading life sciences investment firm. He has authored numerous peer-reviewed publications and holds over 60 patents, with significant contributions spanning basic research, platform technologies, and therapeutic biologics.

At Syngene, Dr. Singh contributes his extensive scientific and strategic expertise as a member of the Nomination & Remuneration Committee, the Science & Technology Committee, and the Corporate Social Responsibility Committee.

With over three decades of extensive experience in the FMCG industry, Mr. Suresh Narayanan has held senior leadership roles across geographies, driving growth and transformation in global markets. In his previous assignment, Mr. Narayanan served as the Chairman and Managing Director of Nestlé India Limited from October 29, 2015, until July 2025. He first joined the company’s Board of Directors as Managing Director on August 1, 2015.

He holds a Master’s degree in Economics from the Delhi School of Economics, a Diploma in Executive Development from IMD, and is an alumnus of the Nestlé Leadership Program at the London Business School. Prior to his appointment in India, Mr. Narayanan served as Chairman and CEO of Nestlé Philippines, where he played a key role in strengthening the business and enhancing its market presence. He began his journey with Nestlé in 1999 as Executive Vice President – Sales, India, where he led significant strategic and structural changes in sales and customer management, including the launch of the company’s chilled dairy business. Mr. Narayanan began his professional career with Hindustan Unilever and subsequently held various roles in Sales, Marketing, and General Management. He also held key positions at Colgate-Palmolive India prior to joining Nestlé. A dynamic and people-focused leader, Mr. Narayanan is widely respected for his integrity, strategic foresight, and inclusive leadership style.

At Syngene, Mr. Narayanan serves as the Chairperson of the Nomination & Remuneration Committee and is a member of the Audit Committee and the Stakeholders Relationship & ESG Committee.